联合治疗未提高接受维得利珠单抗或乌司奴单抗治疗的炎症性肠病患者的临床或内镜缓解率
这项回顾性研究纳入549例接受维得利珠单抗和363例接受乌司奴单抗治疗的克罗恩病或溃疡性结肠炎患者,比较联合免疫调节剂与单药治疗。结果显示,两种药物联合治疗在第14、30、54周的临床应答或缓解率与单药治疗均无显著差异,1年内镜应答率和治疗持续率也相似。
要点
- 维得利珠单抗联合治疗与单药治疗第14周临床应答或缓解率分别为68.2%和74.1%,无显著差异。
- 乌司奴单抗联合治疗与单药治疗第14周临床应答或缓解率分别为54.6%和65.8%,无显著差异。
- 两种药物联合治疗与单药治疗在1年时维持治疗或内镜应答的患者比例相似。
核心结论
- 在接受维得利珠单抗或乌司奴单抗治疗的克罗恩病或溃疡性结肠炎患者中,联合免疫调节剂未提高1年时的临床缓解或应答率、内镜缓解率或治疗持续率。
研究设计与样本
- 回顾性研究,纳入在美国马萨诸塞州总医院、加拿大阿尔伯塔健康科学中心和法国南锡大学医院启动维得利珠单抗或乌司奴单抗治疗且随访至少1年的克罗恩病或溃疡性结肠炎患者,共549例接受维得利珠单抗维持治疗(263例溃疡性结肠炎,286例克罗恩病),363例接受乌司奴单抗维持治疗(4例溃疡性结肠炎,359例克罗恩病),平均病程13-15年。
主要发现
- 维得利珠单抗联合治疗组131例(23.9%;78例使用硫嘌呤,53例使用甲氨蝶呤),乌司奴单抗联合治疗组120例(33.1%;57例使用硫嘌呤,63例使用甲氨蝶呤)。
- 维得利珠单抗联合治疗与单药治疗第14周临床应答或缓解率分别为68.2%和74.1%(P = .22),第30周分别为74.3%和75.6%(P = .78),第54周分别为78.3%和72.9%(P = .33),均无显著差异。
- 乌司奴单抗联合治疗与单药治疗第14周临床应答或缓解率分别为54.6%和65.8%(P = .08),第30周分别为71.6%和77.4%(P = .33),第54周分别为62.1%和67.0%(P = .52),均无显著差异。
- 维得利珠单抗或乌司奴单抗联合治疗与单药治疗在1年时维持治疗或内镜应答的患者比例相似。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Patients with Crohn's disease (CD) or ulcerative colitis (UC) often receive combination therapy with an immunomodulator and tumor necrosis factor antagonists, especially infliximab. However, the benefits of combination therapy with vedolizumab and ustekinumab are unclear. METHODS: We performed a retrospective study of patients with CD or UC initiating vedolizumab or ustekinumab therapy at Massachusetts General Hospital (USA), Alberta Health Sciences (Canada), or Nancy University Hospital (France) with at least 1 year of follow up. The primary outcome was clinical remission or response at week 14, based on the Harvey Bradshaw index for CD or simple clinical colitis index or partial Mayo score for UC. We separately examined week 30 and week 54 clinical outcomes, endoscopic response, and durability of therapy using multivariable regression models and adjusting for relevant confounders. RESULTS: Our study included 549 patients (263 with UC, 286 with CD) receiving maintenance therapy with vedolizumab and 363 patients (4 with UC, 359 with CD) receiving maintenance therapy with ustekinumab with 1 year of follow up. The mean disease duration was 13-15 years. One-hundred thirty-one patients receiving vedolizumab (23.9%; 78 receiving thiopurine, 53 receiving methotrexate) and 120 patients receiving ustekinumab (33.1%, 57 receiving thiopurine, 63 receiving methotrexate) were receiving combination therapy. For vedolizumab, there was no difference in clinical response or remission with combination therapy vs monotherapy at week 14 (68.2% vs 74.1%; P = .22), week 30 (74.3% vs 75.6%; P = .78) or week 54 (78.3% vs 72.9%, P = .33). For ustekinumab, there was no difference in clinical response or remission with combination therapy vs monotherapy at week 14 (54.6% vs 65.8%; P = .08), week 30 (71.6% vs 77.4%; P = .33) or week 54 (62.1% vs 67.0%; P = .52). There were similar proportions of patients remaining on treatment or with endoscopic response at 1 year among patients receiving combination or monotherapy with vedolizumab or ustekinumab. CONCLUSIONS: In patients with CD or UC initiating ustekinumab or vedolizumab therapy, combination therapy with immunomodulators did not increase rates of clinical remission or response, endoscopic remission, or persistence of therapy at 1 year.
引用
- Hu A, Kotze PG, Burgevin A, et al. Combination Therapy Does Not Improve Rate of Clinical or Endoscopic Remission in Patients with Inflammatory Bowel Diseases Treated With Vedolizumab or Ustekinumab. Clin Gastroenterol Hepatol. 2020. PMID: 32668338. doi:10.1016/j.cgh.2020.07.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。